Weight loss moves the needle on PCOS, but not every symptom

Polycystic ovary syndrome is common in women of reproductive age and is associated with obesity, and clinical guidelines routinely recommend weight loss as a treatment. What has been genuinely unclear is whether losing weight actually improves the clinical features women care about: irregular periods, excess hair growth, hormonal markers and quality of life, rather than just body weight itself. This review set out to quantify the effect of weight loss interventions on those features against usual care, and notably, conversations with people who have PCOS informed which outcomes the researchers measured.

The team searched MEDLINE, Embase, PsycINFO, CINAHL, Cochrane, Web of Science and trial registries from inception through June 2024 for randomised controlled trials comparing weight loss interventions with usual care in people with PCOS. Pairs of independent reviewers screened studies, extracted data and assessed risk of bias. The primary analyses covered 29 comparisons with 1529 participants: 12 used behavioural interventions, 9 used GLP-1 agonists and 8 used other weight loss medications. Outcomes included insulin resistance (HOMA-IR), fasting insulin and glucose, the free androgen index and other sex hormones, menstrual frequency, hirsutism and PCOS-related quality of life.

Weight loss interventions were associated with significantly greater improvements on three fronts: HOMA-IR fell by 0.45, the free androgen index fell by 2.03, and menstrual frequency increased by 2.64 compared with usual care. The rest of the picture was flat. There was no evidence of clinically or statistically significant improvement in hirsutism, quality of life or other sex hormones, which the authors suggest may reflect the limited power of the available data rather than a true absence of effect. Of the 29 comparisons, 13 were judged at high risk of bias, 12 at some risk and 4 at low risk, and statistical disagreement between studies was high and largely unexplained.

This review puts firmer numbers behind guideline advice that has often rested on assumption: weight loss genuinely improves insulin resistance, androgen levels and menstrual regularity in PCOS. It also draws a more honest boundary than the guidelines usually do, because hirsutism and quality of life, two outcomes women with PCOS frequently rank highest, showed no measurable benefit here. Whether that gap reflects underpowered trials or a real limit of weight loss as a treatment is the central open question. The mix of behavioural programmes and different drug classes also leaves unresolved which route to weight loss works best.

For anyone with PCOS, this is a reason to think weight loss, achieved through whichever route suits the individual, is associated with real improvements in the metabolic and hormonal machinery of the condition, including more regular cycles. It is equally a reason to hold realistic expectations: the visible and lived-experience outcomes, excess hair growth and quality of life, did not clearly improve in these trials. The authors conclude weight loss interventions should be considered a routine treatment option for PCOS, while the underlying evidence remains uneven in quality.